Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Biojiva LLC has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct art units, showing technical breadth within the biotech field. The company is working with 5 distinct examiners, meaning each of the 5 pending office actions is assigned to a different individual. This ratio of examiners to actions suggests a lack of concentrated examiner influence.
HUI, SAN MING R is the busiest examiner for the portfolio with 1 pending office action. Because 5 distinct examiners are involved in only 5 actions, there is no examiner overlap at this time. This requires the prosecution team to manage the examiner relationships across the 3 distinct art units where these cases are being reviewed. Practitioners should be prepared for different examination styles, as the 5 distinct examiners may each have unique interpretations of the technical standards. The presence of 3 distinct art units further emphasizes the need for a versatile prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| CARR, DEBORAH D | 1 | 81.8% | +2.7% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275972 | Methods for Inhibiting the Progression of Neurodegenerative Diseases | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18772745 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | CARR, DEBORAH D | — |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863394 | Therapeutic Methods for Treating ALS | HUI, SAN MING R | — |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | — |
| 18541375 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863394 | Therapeutic Methods for Treating ALS | HUI, SAN MING R | — | §103Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18772745 | SITE-SPECIFIC ISOTOPIC LABELING OF 1,4-DIENE SYSTEMS | CARR, DEBORAH D | 1691 | §103§112Other | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18767538 | Methods for Treating Tauopathy | FAN, LYNN Y | — | §103§112 | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18541375 | SYNERGISTIC COMBINATION THERAPY FOR TREATING ALS | SCHMITT, MICHAEL J | 1629 | §103DP | Final Rejection | — | Pending | Dec 15, 2023 |
| 18275972 | Methods for Inhibiting the Progression of Neurodegenerative Diseases | INAM, SAHAR | 1622 | §102§103§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial